Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Int J Rad Appl Instrum B. 1986;13:277–9.
McDougall IR. 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun. 1997;18:505–12.
Bajén MT, Mañé S, Muñoz A, Garcia JR. Effect of diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. J Nucl Med. 2000;41:2038–42.
Dam HQ, Kim SM, Lin HC, Intenzo CM. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Radiology. 2004;232:527–33.
Kalinyak JE, McDougall IR. Whole-body scanning with radionuclides of iodine, and the controversy of “thyroid stunning”. Nucl Med Commun. 2004;25:883–9.
Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med Mol Imaging. 2002;29:783–8.
Lassmann M, Luster M, Hänscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45:619–25.
Woolfenden JM. Thyroid stunning revisited. J Nucl Med. 2006;47:1403–5.
Sisson JC, Avram AM, Lawson SA, Gauger PG, Doherty GM. The so-called stunning of thyroid tissues. J Nucl Med. 2006;47:1406–12.
Gerard SK, Park HM. Stunning effect. J Nucl Med. 2007;48:328–9. author reply: 329-330.
Hilditch TE, Bolster AA, Dempsey MF, Reed NS. The so-called stunning of thyroid tissue. J Nucl Med. 2007;48:675–6. author reply: 676.
Filesi M, Colandrea M, Montesano T, D'Apollo R, Ronga G. Thyroid stunning in clinical practice: is it a real problem? Minerva Endocrinol. 2008;34:29–36.
Kalinyak JE, McDougall IR. Whole-body scanning with radionuclides of iodine, and the controversy of “thyroid stunning.”. Nucl Med Commun. 2004;25:883–9.
McDougall IR, Iagaru A. Thyroid stunning: fact or fiction? Semin Nucl Med. 2011;41:105–12.
Postgard P, Himmelman J, Lindencrona U, Bhogal N, Wiberg D, Berg G, et al. Stunning of iodide transport by 131I irradiation in cultured thyroid epithelial cells. J Nucl Med. 2002;43:828–34.
Lundh C, Nordén M, Nilsson M, Forssell-Aronsson E. Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J Nucl Med. 2007;48:481–6.
Nordén MM, Larsson F, Tedelind S, Carlsson T, Lundh C, Forssell-Aronsson E, et al. Down-regulation of the sodium/iodide symporter explains 131I-induced thyroid stunning. Cancer Res. 2007;67:7512–7.
http://www.doseinfo-radar.com/OLINDA.html. Accessed 13 November 2015.
Lundh C, Lindencrona U, Postgård P, Carlsson T, Nilsson M, Forssell-Aronsson E. Radiation-induced thyroid stunning: differential effects of (123)I, (131)I, (99m)Tc, and (211)At on iodide transport and NIS mRNA expression in cultured thyroid cells. J Nucl Med. 2009;50:1161–7.
Cheng W, Ma C, Fu H, Li J, Chen S, Wu S, et al. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. J Clin Endocrinol Metab. 2013;98:1353–60.
Castagna MG, Cevenini G, Theodoropoulou A, Maino F, Memmo S, Claudia C, et al. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol. 2013;169:23–9.
Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS, Song DE, et al. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension. Thyroid. 2014;24:820–5.
Du P, Jiao X, Zhou Y, Li Y, Kang S, Zhang D, et al. Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials. Endocrine. 2015;48:96–105.
Abdulrezzak U, Tutus A, Isik I, Kurt Y, Kula M. The quantitative comparison of low dose and standard dose radio iodine therapy effectiveness in patients with low risk differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2015 Jan 20. [Epub ahead of print]
Brahme A, Agren AK. Optimal dose distribution for eradication of heterogeneous tumors. Acta Oncol. 1987;26:377–85.
Gaussen A, Legal JD, Beron-Gaillard N, Laplanche A, Travagli JP, Caillou B, et al. Radiosensitivity of human normal and tumoral thyroid cells using fluorescence in situ hybridization and clonogenic survival assay. Int J Radiat Oncol Biol Phys. 1999;44:683–91.
Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366–72.
Nahum AE. Converting dose distributions into tumour control probability. IAEA 1996 http://www.iaea.org/inis/collection/NCLCollectionStore/_Public/28/018/28018201.pdf#page=26 Accessed 13 November 2015.
McParland BJ. Nuclear medicine radiation dosimetry: advanced theoretical principles. New York: Springer; 2010. p. 449.
The 2007 recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP. 2007; 37:1-332
Barendsen GW, Walter HM. Effects of different ionizing radiations on human cells in tissue culture. IV modification of radiation damage. Rad Res. 1964;21:314–29.
Johansson L, Leide-Svegborn S, Mattsson S, Nosslin B. Biokinetics of iodide in man: refinement of current ICRP dosimetry models. Cancer Biother Radiopharm. 2003;18:445–50.
Gibson WG, Peng TC, Croker BP. Age-associated C-cell hyperplasia in the human thyroid. Am J Pathol. 1982;106:388–93.
Medvedec M. Seeking a radiobiological explanation for thyroid stunning. Eur J Nucl Med. 2001;28:393–5.
Modoni S, Martino G, Valle G, Perrone E, Frusciante V. How is thyroid remnant ablation affected by former 131-1 diagnostic doses and/or elapsed time? Eur J Nucl Med Mol Imaging. 2000;27:1152.
Kappler M, Rot S, Taubert H, Greither T, Bartel F, Dellas K et al. The effects of knockdown of wild-type survivin, survivin-2B or survivin-delta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions. Cancer Gene Ther. 2007;14:994–1001.
Amin A, Amin M, Badwey A. Stunning phenomenon after a radioactive iodine- 131I diagnostic whole-body scan: is it really a point of clinical consideration? Nucl Med Commun. 2013;34:771–6.
El-Saban K, Al-Sakhri H, Al-Zahrani A. Effect of stunning of diagnostic 131-iodine doses on ablative doses for differentiated thyroid cancer patient’s outcome. J Sol Tum. 2013;3:11–9.
Yap BK, Murby B. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect. J Clin Endocrinol Metab. 2014;99:2433–40.
Etchebehere EC, Santos AO, Matos PS, Assumpção LV, Lima MC, Lima MC, et al. Is thyroid stunning clinically relevant? A retrospective analysis of 208 patients. Arq Bras Endocrinol Metabol. 2014;58:292–300.
Hu YH, Wang PW, Wang ST, Lee CH, Chen HY, Chou FF, et al. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation. Nucl Med Commun. 2004;25:793–7.
Verburg FA, Verkooijen RB, Stokkel MP, van Isselt JW. The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I. Nuklearmedizin. 2009;48:138–42.